Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Idexx Laboratories (IDXX)

Idexx Laboratories (IDXX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,040,960
  • Shares Outstanding, K 85,300
  • Annual Sales, $ 2,407 M
  • Annual Income, $ 427,720 K
  • 60-Month Beta 0.88
  • Price/Sales 16.51
  • Price/Cash Flow 82.57
  • Price/Book 96.00
Trade IDXX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.43
  • Number of Estimates 4
  • High Estimate 1.49
  • Low Estimate 1.37
  • Prior Year 1.04
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
479.36 +2.82%
on 01/06/21
516.86 -4.64%
on 01/11/21
-6.29 (-1.26%)
since 12/22/20
3-Month
419.12 +17.59%
on 10/30/20
516.86 -4.64%
on 01/11/21
+69.27 (+16.35%)
since 10/22/20
52-Week
168.65 +192.24%
on 03/23/20
516.86 -4.64%
on 01/11/21
+205.24 (+71.36%)
since 01/22/20

Most Recent Stories

More News
Intuitive Surgical (ISRG) Q4 Earnings Beat Estimates, Up Y/Y

Intuitive Surgical's (ISRG) fourth-quarter results reflect improvement in procedure volume.

ISRG : 744.08 (-6.84%)
HOLX : 75.70 (-0.29%)
IDXX : 492.86 (-0.72%)
NXGN : 22.95 (+5.61%)
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now

AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.

XRAY : 57.23 (-0.71%)
PDCO : 32.50 (+3.67%)
AMN : 75.08 (+2.75%)
IDXX : 492.86 (-0.72%)
Why You Should Retain Pacific Biosciences (PACB) Stock Now

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.

HOLX : 75.70 (-0.29%)
PKI : 151.91 (+0.88%)
IDXX : 492.86 (-0.72%)
PACB : 37.42 (+3.06%)
ESG Stocks to Gather Speed Under Biden's Leadership: 5 Picks

Biden's administration plans to address climate change and take ESG initiatives. This call for investing in Shopify (SHOP), Magna International (MGA), IDEXX Lab (IDXX), Facebook (FB) and PayPal (PYPL)....

MGA : 76.00 (-1.36%)
IDXX : 492.86 (-0.72%)
FB : 274.50 (+0.60%)
PYPL : 252.00 (+1.35%)
SHOP : 1,196.70 (-0.12%)
Here's Why You Should Add Hologic (HOLX) to Your Portfolio

Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.

OMCL : 123.23 (+2.33%)
HOLX : 75.70 (-0.29%)
PDCO : 32.50 (+3.67%)
IDXX : 492.86 (-0.72%)
Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results

Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.

OMCL : 123.23 (+2.33%)
HOLX : 75.70 (-0.29%)
PKI : 151.91 (+0.88%)
IDXX : 492.86 (-0.72%)
Cardiovascular Systems' (CSII) OAS Gets CE Mark for Use in Europe

Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.

HOLX : 75.70 (-0.29%)
PDCO : 32.50 (+3.67%)
IDXX : 492.86 (-0.72%)
CSII : 46.65 (-0.30%)
Haemonetics (HAE) Hits New 52-Week High: What's Driving It?

Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

MDT : 116.58 (-1.13%)
HOLX : 75.70 (-0.29%)
HAE : 116.92 (-0.92%)
IDXX : 492.86 (-0.72%)
Quest Diagnostics (DGX) COVID-19 Test Sales Solid, Volume Dull

Quest Diagnostics (DGX) notes strong signs of the healthcare system returning to pre-pandemic levels with base testing volume gradually improving.

DGX : 124.46 (-0.58%)
HOLX : 75.70 (-0.29%)
PDCO : 32.50 (+3.67%)
IDXX : 492.86 (-0.72%)
Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing

Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.

HOLX : 75.70 (-0.29%)
PKI : 151.91 (+0.88%)
IDXX : 492.86 (-0.72%)
XENT : 26.60 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff...

See More

Key Turning Points

3rd Resistance Point 506.87
2nd Resistance Point 502.92
1st Resistance Point 497.89
Last Price 492.86
1st Support Level 488.92
2nd Support Level 484.97
3rd Support Level 479.94

See More

52-Week High 516.86
Last Price 492.86
Fibonacci 61.8% 383.85
Fibonacci 50% 342.76
Fibonacci 38.2% 301.67
52-Week Low 168.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar